Advanced Biomed Inc

This proposal asks shareholders to cast a non-binding advisory vote to approve the overall compensation paid to the Company’s named executive officers as disclosed in the proxy statement, including tables and narrative disclosure. Management is seeking shareholder approval to receive feedback and validate its compensation philosophy, which it describes as aimed at attracting, retaining, and motivating executives and aligning executive interests with long-term stockholder value. The vote is required by Section 14A of the Exchange Act but is advisory and non-binding; the Board and Compensation Committee state they will consider the outcome when setting future pay. Contextually, the Company’s pay program for the reported year was largely fixed and retention-focused, with base salaries and no equity grants or performance bonuses paid, reflecting a development-stage focus on cash preservation. The Board’s recommendation to vote FOR is supported by its view that the disclosed practices are appropriate for the Company’s stage and objectives and that shareholder input is useful for future determinations. Since no equity awards were granted to NEOs during the period, the practical effect of the vote is to endorse the disclosed cash-centric arrangements and governance processes described. A ‘‘FOR’’ vote signals to management that shareholders generally accept the current mix of pay elements and governance controls (e.g., Compensation Committee oversight, clawback policy), while a negative vote would likely prompt the Board to engage with major holders and potentially adjust compensation practices. The advisory nature of the vote means it will not directly change pay, but it can influence future compensation design and disclosure practices, especially given the Company’s stated intention to consider results in compensation decisions.

This proposal asks shareholders to select, on a non-binding advisory basis, whether future advisory votes on named executive officer compensation should occur every one, two, or three years. Management recommends an annual (one year) frequency, arguing that it provides the timeliest and most direct opportunity for shareholders to express views on executive pay and to engage regularly with governance decisions. The vote is a compliance mechanism under Section 14A and is advisory; the Board may nevertheless choose a different cadence if it believes that is in stockholders’ best interest, but it has signaled an intent to heed results. Company-specific context includes a near-term expectation for the next advisory vote to occur in 2027 and a compensation program that is currently cash-focused with limited use of equity incentives, so frequent shareholder feedback may be particularly relevant as compensation design evolves. For investors, an annual vote increases the frequency of shareholder communication and can accelerate responsiveness to concerns about pay design, while multi-year votes can reduce administrative burden and allow longer-term pay plans to be evaluated. The Board’s emphasis on annual votes aligns with an active engagement posture during the Company’s strategic pivot to AI technologies and recent leadership changes, which could prompt more frequent compensation adjustments. Because the vote is non-binding, the governance implication depends on the Board’s responsiveness; a strong shareholder preference for a particular frequency would likely shape subsequent disclosure and engagement practices. Overall, an annual recommendation reflects a desire for ongoing shareholder oversight during a period of operational and leadership transition.

This management proposal asks shareholders to authorize the Board to adjourn the Annual Meeting, if necessary, to solicit additional proxies or to allow timely distribution of any supplement or amendment to the proxy materials. Management seeks this authorization as a procedural mechanism to address situations where there are insufficient votes to approve one or more proposals at the scheduled meeting time, enabling the Company to continue solicitation or correct/share additional disclosure without reconvening under a newly noticed meeting. The Board recommends approval to preserve flexibility and to maximize the likelihood of reaching vote outcomes consistent with corporate needs and governance timelines. The adjournment power is commonly used to extend solicitation time, and the filing explains that an adjournment of no more than 30 days requires no additional notice if announced at the meeting, avoiding further administrative burden. For stockholders, approval provides the Company with an ability to secure fuller participation, but abstentions will count as votes against this proposal and could affect the outcome; broker non-votes will not affect the result. Approving adjournment can protect against the risk that narrow vote margins or last-minute information changes prevent the Company from implementing approved actions or from providing required disclosures. The Board’s recommendation reflects its view that having this tool is in stockholders’ best interest to ensure orderly consideration of matters and to give management an opportunity to address any shortfall in votes through additional outreach. If approved, the Company may use adjournment sparingly and only as described, consistent with the proxy statement’s procedures and the Board’s fiduciary duties.